XML 41 R32.htm IDEA: XBRL DOCUMENT
v3.22.2

Significant events and changes in the current reporting period - Additional information (Detail) € in Thousands, $ in Millions |  |  | 3 Months Ended | 6 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 01, 2022 USD ($) | Jun. 01, 2022 EUR (€) | Jan. 26, 2022 USD ($) | Jan. 26, 2022 EUR (€) | Jun. 30, 2022 EUR (€) | Jun. 30, 2022 EUR (€) | Jun. 30, 2022 USD ($) | Jun. 30, 2022 EUR (€) | Mar. 31, 2022 USD ($) | Mar. 31, 2022 EUR (€) | Jan. 26, 2022 EUR (€) | Dec. 31, 2021 EUR (€)
Disclosure of changes in accounting policies accounting estimates and errors [line items] |  |  |  |  |  |  |  |  |  |  |  |
Contract liabilities |  |  |  |  |  |  |  | € 193,715 |  |  |  | € 98,627
Immatics Biotechnologies GmbH [member] |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of changes in accounting policies accounting estimates and errors [line items] |  |  |  |  |  |  |  |  |  |  |  |
Transaction price allocation to performance obligation |  |  | $ 150 |  |  |  |  |  |  |  | € 133,000 |
License Development and Commercialization Agreement [member] | Bristol Myer Squib Company [member] | Immatics US Inc [member] |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of changes in accounting policies accounting estimates and errors [line items] |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received | $ 60 | € 57,700 |  |  |  |  |  |  |  |  |  |
Additional payment related to performance obligations received | 5 | 4,800 |  |  |  |  |  |  |  |  |  |
Milestone regulatory and royaly payment receivable | $ |  |  |  |  |  |  | $ 700 |  |  |  |  |
Transaction price allocation to performance obligation |  |  |  |  |  |  |  | 60,700 |  |  |  |
Revenue recognized during the period performance obligation |  |  |  |  | € 600 |  |  |  |  |  |  |
Amendment to the Strategic Collaboration Agreement [member] | Bristol Myer Squib Company [member] | Immatics Biotechnologies GmbH [member] |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of changes in accounting policies accounting estimates and errors [line items] |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received | $ 20 | € 18,700 |  |  |  |  |  |  |  |  |  |
Transaction price allocation to performance obligation |  |  |  |  |  |  | $ 20 | 18,700 |  |  |  |
Revenue recognized during the period performance obligation |  |  |  |  | 0 |  |  |  |  |  |  |
BMS Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of changes in accounting policies accounting estimates and errors [line items] |  |  |  |  |  |  |  |  |  |  |  |
Contract liabilities |  |  |  |  |  |  |  | € 42,000 |  |  |  |
BMS Agreement [Member] | Immatics Biotechnologies GmbH [member] |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of changes in accounting policies accounting estimates and errors [line items] |  |  |  |  |  |  |  |  |  |  |  |
Receipt of upfront of payment |  |  | 150 | € 133,000 |  |  |  |  |  |  |  |
Allocation of upfront payment towards clinical trial services and license grant |  |  |  |  |  |  |  |  | $ 150 | € 133,000 |  |
Allocation of upfront payment towards clinical trial services |  |  |  |  |  |  |  |  |  | 42,000 |  |
Allocation of upfront payment towards license grant |  |  |  |  |  |  |  |  |  | € 91,000 |  |
BMS Agreement [Member] | Immatics Biotechnologies GmbH [member] | Development Regulatory and Commercial Milestone [Member] |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of changes in accounting policies accounting estimates and errors [line items] |  |  |  |  |  |  |  |  |  |  |  |
Development regulatory and commercial milestone payments receivable | $ |  |  | $ 770 |  |  |  |  |  |  |  |  |
BMS Agreement [Member] | Immatics Biotechnologies GmbH [member] | IMA 401 License Grant [Member] |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of changes in accounting policies accounting estimates and errors [line items] |  |  |  |  |  |  |  |  |  |  |  |
Revenue from contracts with customers |  |  |  |  |  | € 91,000 |  |  |  |  |  |
BMS Agreement [Member] | Immatics Biotechnologies GmbH [member] | IMA 401 Clinical Trial Services [Member] |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of changes in accounting policies accounting estimates and errors [line items] |  |  |  |  |  |  |  |  |  |  |  |
Revenue from contracts with customers |  |  |  |  | € 2,800 | € 4,300 |  |  |  |  |  |

X
- Definition The amount of an entity’s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2021-01-01 -Paragraph 105 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_105&doctype=Standard -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2021-01-01 -Paragraph 116 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_116_a&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_ContractLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2021-01-01 -Paragraph 113 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_113_a&doctype=Standard -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2021-01-01 -Paragraph 114 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2021-01-01 -Paragraph 120 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_a&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Additional payment related to performance obligations received. + References No definition available. + Details
Name: | imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived
Namespace Prefix: | imtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Allocation of upfront payment towards clinical trial services. + References No definition available. + Details
Name: | imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServices
Namespace Prefix: | imtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Allocation of upfront payment towards clinical trial services and license grant. + References No definition available. + Details
Name: | imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant
Namespace Prefix: | imtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Allocation of upfront payment towards license grant. + References No definition available. + Details
Name: | imtx_AllocationOfUpfrontPaymentTowardsLicenseGrant
Namespace Prefix: | imtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Development regulatory and commercial milestone payments receivable. + References No definition available. + Details
Name: | imtx_DevelopmentRegulatoryAndCommercialMilestonePaymentsReceivable
Namespace Prefix: | imtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Disclosure of changes in accounting policies accounting estimates and errors. + References No definition available. + Details
Name: | imtx_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsLineItems
Namespace Prefix: | imtx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone regulatory and royalty payment received. + References No definition available. + Details
Name: | imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived
Namespace Prefix: | imtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Receipt of upfront of payment. + References No definition available. + Details
Name: | imtx_ReceiptOfUpFrontOfPayment
Namespace Prefix: | imtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue recognized during the period performance obligation. + References No definition available. + Details
Name: | imtx_RevenueRecognizedDuringThePeriodPerformanceObligation
Namespace Prefix: | imtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront payment received. + References No definition available. + Details
Name: | imtx_UpfrontPaymentReceived
Namespace Prefix: | imtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsBiotechnologiesGmbhMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | imtx_AgreementAxis=imtx_LicenseDevelopmentAndCommercializationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=imtx_BristolMyerSquibCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsUsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | imtx_AgreementAxis=imtx_AmendmentToTheStrategicCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | imtx_AgreementAxis=imtx_BmsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | imtx_MilestoneAxis=imtx_DevelopmentRegulatoryAndCommercialMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=imtx_Ima401LicenseGrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=imtx_Ima401ClinicalTrialServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |